Management of Cellular Rejection Post Liver Transplantation

Introduction to Cellular Rejection

The cornerstone of treatment for cellular rejection after liver transplantation is high-dose corticosteroids, typically administered as intravenous methylprednisolone, followed by calcineurin inhibitor optimization, with tacrolimus being the preferred agent in most centers 1, 2

Acute cellular rejection occurs in up to 10% of liver transplant recipients, most commonly within the first 3 months but can occur at any time post-transplantation 2
Diagnosis requires liver biopsy after exclusion of vascular or biliary complications 2
Clinical presentation may include abnormal liver function tests, fever, jaundice, and abdominal pain in advanced cases 2
Patients with autoimmune liver diseases are at higher risk for early and late cellular rejection than other liver transplant indications 1

Calcineurin inhibitors are the cornerstone of maintenance immunosuppression 3, 4
Tacrolimus is typically preferred over cyclosporine due to lower rejection rates and more widespread use in the United States 2, 3, 4
Target tacrolimus trough levels are 5-15 ng/ml early post-transplant and approximately 5 ng/ml long-term 4
Cyclosporine trough levels are 200-300 ng/ml early post-transplant and 50-150 ng/ml long-term 4

Chronic rejection may develop if not adequately treated, presenting as vanishing bile duct syndrome, severe biliary obstruction and jaundice, and often associated with renal dysfunction 2

For patients with recurrent rejection episodes, consider double immunosuppression with addition of mycophenolate mofetil or maintenance low-dose prednisolone 1

Regular monitoring of liver function tests is essential 3
Drug level monitoring is critical due to the narrow therapeutic window of CNIs 5
Monitor for adverse effects of immunosuppression, including infections, renal dysfunction, and metabolic complications 2, 6

Avoid medications that alter CNI metabolism through cytochrome P-450 3A4 and P-glycoprotein pathways 5
Common medications to avoid include NSAIDs, certain antibiotics, anticonvulsants, and St. John's Wort 5, 6

For patients at high risk of rejection, basiliximab induction therapy is commonly used and consider more intensive maintenance immunosuppression 1
Medication adherence is critical, as non-compliance is associated with late rejection episodes 2